Oncology · Brain TumorsTrial Updateclinicalmid-term

Study on SONDA Visual Field Test for Patients with Supra Sellar Tumors

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/25/2026, 6:31:40 PM

Assessment confidence: 73% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial evaluating the SONDA visual field test for supra sellar tumors could significantly influence diagnostic practices in oncology. A successful outcome may lead to its adoption as a standard tool, impacting treatment protocols and patient management strategies. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 25 ranked evidence items (16 high-relevance).

Strategic Assessment

If successful, the SONDA test may become a standard diagnostic tool, influencing product development and clinical practices in oncology. The strongest clinical anchor is Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) (ClinicalTrials.gov), sponsor/company relevance (novartis). In Oncology · Brain Tumors, 3 regulatory and 6 competitive items passed relevance filtering for brain tumor diagnostics.

Competitive Pressure

The most relevant competitive pressure comes from Roche receives CE Mark for blood test to identify tuberculosis infection (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE Mark for blood test to identify tuberculosis infection. This study could provide insights into diagnostic tools for brain tumors, potentially impacting treatment approaches and patient management.

Regulatory Outlook

Regulatory risk is concentrated around FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients (FDA). Moderate corpus alignment. The trial results could lead to new regulatory approvals for the SONDA test, affecting compliance and labeling for diagnostic tools in oncology.

Key Risks

Elevated medium regulatory exposure for brain tumor diagnostics could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If the SONDA test is validated, it could enhance market share for companies involved in brain tumor diagnostics and influence future product development in this therapeutic area.
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.
Upside for brain tumor diagnostics may improve if Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (ClinicalTrials.gov) delivers favorable follow-through.
Upside for brain tumor diagnostics may improve if Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors (ClinicalTrials.gov) delivers favorable follow-through.
Upside for brain tumor diagnostics may improve if Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any subsequent adoption of the SONDA test in clinical settings.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Condition-Specific Meeting Reports and Other Information Related to Patients' Experience
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Perimetry Based on Eye-movements in Patients With (Supra)Sellar Tumors
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche receives CE Mark for blood test to identify tuberculosis infection
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE Mark for blood test to identify tuberculosis infection
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Astellas Pharma initiates trial of ASP2138 for HER2-negative gastric cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
Zanubrutinib Plus Anti-CD20 Shows Promise in R/R Follicular and Marginal Zone Lymphoma Study
Humanexa Signalsmedium relevance
Moderate corpus alignment

Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Unveiling the cognitive fog in lung cancer patients: non-invasive exploration of blood-brain barrier disruption and brain structural changes.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Changes of body composition through an athlete-specific dietary guidance professional track and field athletes: a randomized controlled study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

brain tumor diagnostics

Commercial impact

medium

If the SONDA test is validated, it could enhance market share for companies involved in brain tumor diagnostics and influence future product development in this therapeutic area.

Regulatory impact

medium

The trial results could lead to new regulatory approvals for the SONDA test, affecting compliance and labeling for diagnostic tools in oncology.

What to watch

Monitor trial results and any subsequent adoption of the SONDA test in clinical settings.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.